Pharma: Clinic Roundup
Janssen Research & Development, of Raritan, N.J., a unit of Johnson & Johnson, reported findings showing that subcutaneous induction regimens of anti-TNF-alpha therapy Simponi (golimumab) induced clinical response in a majority of patients with moderately to severely active ulcerative colitis who had previously failed or were intolerant to conventional agents.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.